Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention GLP-1, the most common co-covered peer. We currently track 1 Biotech story that mention Mike Doustdar, all published on August 10, 2026.
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention GLP-1, the most common co-covered peer. We currently track 1 Biotech story that mention Mike Doustdar, all published on August 10, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mike Doustdar. Shared-story counts are live from our verified record — not editorial picks.
Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Source: tickerreport.com · finance.yahoo.com
Mike Doustdar is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
